Research Communications of the 27(th) ECVIM-CA Congress: Intercontinental, Saint Julian's, Malta, 14th to 16th September 2017

All cases showed an improvement clinically, including resolution of jaundice (4/4), vomiting (5/5) and polyuria/polydipsia (4/4). Two out of the 14 cases were euthanized due to CH while receiving prednisolone, with survival times of 122 and 741 days from diagnosis. The remaining 12 patients are alive and clinically well, with 9 patients still receiving a mean dose of 0.4 mg/kg prednisolone every other day (EOD) [range: 0.25 mg/kg/EOD-1 mg/ kg/day]. The median time since diagnosis is 630 days [range: 60-1350 days]. Two-sided Wilcoxon test demonstrated significant (P < 0.05) reductions in serum ALKP, ALT and bilirubin following prednisolone therapy. Median values before and immediately after starting immunosuppressive doses of prednisolone were 810 to 403 iu/L, 1000 to 299 iu/L and 24.0 to 4.0 lmol/L for ALKP, ALT and bilirubin respectively.